Heparan sulfate proteoglycans in the human sclerosing and scarring kidney. Changes in heparan sulfate moiety.
Morita
H
H
Branch Hospital, Nagoya University, School of Medicine, Japan.
David
G
G
Mizutani
A
A
Shinzato
T
T
Habuchi
H
H
Maeda
K
K
Kimata
K
K
D000911:Antibodies, Monoclonal / Q000276:immunology; D001665:Binding Sites; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism; D005355:Fibrosis; D005923:Glomerulosclerosis, Focal Segmental / Q000378:metabolism*; D019812:Heparan Sulfate Proteoglycans; D006497:Heparan Sulfate / Q000378:metabolism*; D006801:Humans; D007124:Immunoenzyme Techniques; D007668:Kidney / Q000378:metabolism / Q000473:pathology*; D011509:Proteoglycans / Q000378:metabolism*
D000911:Antibodies, Monoclonal; D016222:Fibroblast Growth Factor 2; D019812:Heparan Sulfate Proteoglycans; D006497:Heparan Sulfate; D011509:Proteoglycans